<?xml version='1.0' encoding='utf-8'?>
<document id="9574812"><sentence text="Investigation of the potential interaction between terfenadine and tedisamil in human liver microsomes."><entity charOffset="51-62" id="DDI-PubMed.9574812.s1.e0" text="terfenadine" /><entity charOffset="67-76" id="DDI-PubMed.9574812.s1.e1" text="tedisamil" /><pair ddi="false" e1="DDI-PubMed.9574812.s1.e0" e2="DDI-PubMed.9574812.s1.e0" /><pair ddi="false" e1="DDI-PubMed.9574812.s1.e0" e2="DDI-PubMed.9574812.s1.e1" /></sentence><sentence text="1" /><sentence text=" The potential drug-drug interaction of terfenadine and tedisamil has been investigated"><entity charOffset="40-51" id="DDI-PubMed.9574812.s3.e0" text="terfenadine" /><entity charOffset="56-65" id="DDI-PubMed.9574812.s3.e1" text="tedisamil" /><pair ddi="false" e1="DDI-PubMed.9574812.s3.e0" e2="DDI-PubMed.9574812.s3.e0" /><pair ddi="false" e1="DDI-PubMed.9574812.s3.e0" e2="DDI-PubMed.9574812.s3.e1" /></sentence><sentence text=" Terfenadine is a widely used antihistamine drug with the potential for QTC prolongation"><entity charOffset="1-12" id="DDI-PubMed.9574812.s4.e0" text="Terfenadine" /></sentence><sentence text=" Tedisamil is a potassium channel blocking agent known to produce bradycardia and prolong the effective refractory period in man"><entity charOffset="1-10" id="DDI-PubMed.9574812.s5.e0" text="Tedisamil" /><entity charOffset="16-25" id="DDI-PubMed.9574812.s5.e1" text="potassium" /><pair ddi="false" e1="DDI-PubMed.9574812.s5.e0" e2="DDI-PubMed.9574812.s5.e0" /><pair ddi="false" e1="DDI-PubMed.9574812.s5.e0" e2="DDI-PubMed.9574812.s5.e1" /></sentence><sentence text=" 2" /><sentence text=" Tedisamil and terfenadine were incubated with human liver microsomes for 30 min at 37 degrees C"><entity charOffset="1-10" id="DDI-PubMed.9574812.s7.e0" text="Tedisamil" /><entity charOffset="15-26" id="DDI-PubMed.9574812.s7.e1" text="terfenadine" /><pair ddi="false" e1="DDI-PubMed.9574812.s7.e0" e2="DDI-PubMed.9574812.s7.e0" /><pair ddi="false" e1="DDI-PubMed.9574812.s7.e0" e2="DDI-PubMed.9574812.s7.e1" /></sentence><sentence text=" No significant inhibition of terfenadine biotransformation was seen with 0"><entity charOffset="30-41" id="DDI-PubMed.9574812.s8.e0" text="terfenadine" /></sentence><sentence text="1 or 10 microM tedisamil as the formation of the terfenadine alcohol and acid metabolites were unaffected"><entity charOffset="49-68" id="DDI-PubMed.9574812.s9.e0" text="terfenadine alcohol" /></sentence><sentence text=" 3" /><sentence text=" Based on the in vitro results it is suggested that tedisamil will not interact pharmacokinetically with terfenadine as it does not impair metabolism of terfenadine"><entity charOffset="105-116" id="DDI-PubMed.9574812.s11.e0" text="terfenadine" /><entity charOffset="153-164" id="DDI-PubMed.9574812.s11.e1" text="terfenadine" /><pair ddi="false" e1="DDI-PubMed.9574812.s11.e0" e2="DDI-PubMed.9574812.s11.e0" /><pair ddi="false" e1="DDI-PubMed.9574812.s11.e0" e2="DDI-PubMed.9574812.s11.e1" /></sentence><sentence text="" /></document>